Ahlgren J - Search Results

1

Can axillary dissection be avoided by improved molecular biological diagnosis?

Lindahl T, Engel G, Ahlgren J, Klaar S, Bjöhle J, Lindman H, Andersson J, von Schoultz E, Bergh J. Lindahl T, et al. Among authors: ahlgren j. Acta Oncol. 2000;39(3):319-26. doi: 10.1080/028418600750013087. Acta Oncol. 2000. PMID: 10987228 Review.

2

Prediction of axillary lymph node metastases in a screened breast cancer population. South-East Sweden Breast Cancer Group.

Ahlgren J, Stål O, Westman G, Arnesson LG. Ahlgren J, et al. Acta Oncol. 1994;33(6):603-8. doi: 10.3109/02841869409121769. Acta Oncol. 1994. PMID: 7946435

3

Cross-comparison of two quality of life instruments used in a randomized study of combination chemotherapy in advanced breast cancer.

Westman G, Ahlgren J, Jansson T, Bergh J. Westman G, et al. Among authors: ahlgren j. Acta Oncol. 1999;38(5):567-72. doi: 10.1080/028418699431140. Acta Oncol. 1999. PMID: 10427944

4

Omitting axillary surgery for low-risk breast cancer patients--a Swedish prospective cohort study.

Arnesson LG, Ahlgren J. Arnesson LG, et al. Among authors: ahlgren j. Acta Oncol. 2000;39(3):291-4. doi: 10.1080/028418600750013032. Acta Oncol. 2000. PMID: 10987223

5

Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers.

Norberg T, Klaar S, Lindqvist L, Lindahl T, Ahlgren J, Bergh J. Norberg T, et al. Among authors: ahlgren j. Clin Chem. 2001 May;47(5):821-8. Clin Chem. 2001. PMID: 11325884

6

Angiogenesis in invasive breast carcinoma--a prospective study of tumour heterogeneity.

Ahlgren J, Risberg B, Villman K, Bergh J. Ahlgren J, et al. Eur J Cancer. 2002 Jan;38(1):64-9. doi: 10.1016/s0959-8049(01)00349-5. Eur J Cancer. 2002. PMID: 11750841

7

Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer.

Ahlgren J, Holmberg L, Bergh J, Liljegren G. Ahlgren J, et al. Eur J Surg Oncol. 2002 Mar;28(2):97-102. doi: 10.1053/ejso.2001.1228. Eur J Surg Oncol. 2002. PMID: 11884042

8

A Phase I study of CHS 828 in patients with solid tumor malignancy.

Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lönnebo A, Ahlgren J. Hovstadius P, et al. Among authors: ahlgren j. Clin Cancer Res. 2002 Sep;8(9):2843-50. Clin Cancer Res. 2002. PMID: 12231525 Clinical Trial.

9

Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.

Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J. Lindahl T, et al. Among authors: ahlgren j. Carcinogenesis. 2004 Mar;25(3):375-80. doi: 10.1093/carcin/bgh019. Epub 2003 Nov 21. Carcinogenesis. 2004. PMID: 14633656

10

A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.

Villman K, Ohd JF, Lidbrink E, Malmberg L, Lindh B, Blomqvist C, Nordgren H, Bergh J, Bergström D, Ahlgren J. Villman K, et al. Among authors: ahlgren j. Eur J Cancer. 2007 May;43(7):1153-60. doi: 10.1016/j.ejca.2007.02.002. Epub 2007 Mar 29. Eur J Cancer. 2007. PMID: 17398088 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters